The Center for Medical Engineering and Informatics, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0879, Japan.
Biochem Biophys Res Commun. 2012 Sep 7;425(4):859-65. doi: 10.1016/j.bbrc.2012.08.004. Epub 2012 Aug 7.
Transplantation of human cardiomyoblast-like cells (hCLCs) from human adipose tissue-derived multi-lineage progenitor cells improved left ventricular function and survival of rats with myocardial infarction. Here we examined the effect of intracoronary artery transplantation of human CLCs in a swine model of chronic heart failure. Twenty-four pigs underwent balloon-occlusion of the first diagonal branch followed by reperfusion, with a second balloon-occlusion of the left ascending coronary artery 1 week later followed by reperfusion. Four weeks after the second occlusion/reperfusion, 17 of the 18 surviving animals with severe chronic MI (ejection fraction <35% by echocardiography) were immunosuppressed then randomly assigned to receive either intracoronary artery transplantation of hCLCs hADMPCs or placebo lactic Ringer's solution with heparin. Intracoronary artery transplantation was followed by the distribution of DiI-stained hCLCs into the scarred myocardial milieu. Echocardiography at post-transplant days 4 and 8 weeks showed rescue and maintenance of cardiac function in the hCLCs transplanted group, but not in the control animals, indicating myocardial functional recovery by hCLCs intracoronary transplantation. At 8 week post-transplantation, 7 of 8 hCLCs transplanted animals were still alive compared with only 1 of the 5 control (p=0.0147). Histological studies at week 12 post-transplantation demonstrated engraftment of the pre DiI-stained hCLCs into the scarred myocardium and their expression of human specific alpha-cardiac actin. Human alpha cardiac actin-positive cells also expressed cardiac nuclear factors; nkx2.5 and GATA-4. Our results suggest that intracoronary artery transplantation of hCLCs is a potentially effective therapeutic strategy for future cardiac tissue regeneration.
人脂肪组织多能祖细胞来源的人心肌细胞样细胞(hCLCs)移植可改善心肌梗死大鼠的左心室功能和存活率。在此,我们研究了冠状动脉内移植 hCLCs 对猪慢性心力衰竭模型的影响。24 只猪接受第一对角支球囊阻塞,再灌注,1 周后再接受左升主冠状动脉第二次球囊阻塞,再灌注。第二次阻塞/再灌注后 4 周,18 只存活的严重慢性 MI(超声心动图射血分数<35%)动物中的 17 只接受免疫抑制治疗,然后随机分为冠状动脉内移植 hCLCs 或 hADMPCs 或安慰剂乳酸林格氏液加肝素组。冠状动脉内移植后,DiI 标记的 hCLCs 分布到瘢痕心肌环境中。移植后 4 天和 8 周的超声心动图显示 hCLCs 移植组心脏功能的挽救和维持,但对照组动物没有,表明 hCLCs 冠状动脉内移植可实现心肌功能恢复。移植后 8 周,8 只 hCLCs 移植动物中有 7 只仍存活,而对照组只有 5 只中的 1 只存活(p=0.0147)。移植后 12 周的组织学研究表明,预 DiI 标记的 hCLCs 移植到瘢痕心肌中,并表达人特异性α-心脏肌动蛋白。α-心脏肌动蛋白阳性细胞还表达心脏核因子;nkx2.5 和 GATA-4。我们的结果表明,冠状动脉内移植 hCLCs 是未来心脏组织再生的一种潜在有效治疗策略。